TP53 and PTEN coalterations are found in 17% of localized prostate cancer and 16% of metastatic castration-sensitive prostate cancer, increasing to 56% for metastatic castration-resistant prostate cancers (66). This evidence concerns the gene PTEN and prostate carcinoma.